Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02048150 · ClinicalTrials.gov registry record · Phase 1
Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02048150 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT02048150, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the best dose of anti-prostate specific membrane antigen (PSMA) monoclonal antibody MDX1201-A488 (MDX1201-A488) given before surgery to aid in visualization of the prostate. Attaching a fluorescence, a substance that emits radiation that is visible, to the anti-PMSA antibody and injecting it into the body may help identify the tumor when specialized microscopes are used.
Interventions
- OTHER pharmacological study
- PROCEDURE robot-assisted laparoscopic surgery
- OTHER Laboratory Biomarker
- BIOLOGICAL anti-PSMA monoclonal antibody MDX1201-A488
- OTHER diffuse optical imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-03-13 |
| Est. Completion | 2023-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02048150
The ClinicalTrials.gov registry entry for NCT02048150 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which pharmacological study is the first listed.
NCT02048150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02048150 about?
NCT02048150 is a clinical study titled "Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer". This pilot clinical trial studies the best dose of anti-prostate specific membrane antigen (PSMA) monoclonal antibody MDX1201-A488 (MDX1201-A488) given before surgery to aid in visualization of the prostate. Attaching a fluorescence, a substance that emits radiation that is visible, to the anti-PMSA...
What is the current status of trial NCT02048150?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2015-03-13. Estimated completion is 2023-02-01.
What interventions are being tested in trial NCT02048150?
The interventions under investigation include: pharmacological study (OTHER), robot-assisted laparoscopic surgery (PROCEDURE), Laboratory Biomarker (OTHER), anti-PSMA monoclonal antibody MDX1201-A488 (BIOLOGICAL), diffuse optical imaging (OTHER).
Who is sponsoring clinical trial NCT02048150?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.